ASCO 2025: GLP-1 receptor agonists may slightly reduce risk of fourteen obesity-related cancers for people with diabetes
A large observational study of more than 170,000 patients with diabetes and obesity in the…
Browsing: ASCO
ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer
The international phase 3 DESTINY-Gastric04 clinical trial found that second-line treatment with trastuzumab deruxtecan can help…
ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129
The Ental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, has…
ASCO 2025 Special Part 1! S3E4 The Oncology Journal Club
Welcome to Part 1 of the 2025 ASCO ASM Special of The Oncology Journal Club! Our Host Craig Underhill is joined by Dr Kate Clarke and Professor Christopher Jackson to unpack practice changing presentations from Chicago.
ASCO 2025: Adding niraparib to standard treatment may slow cancer growth for some patients with mCSPC
Results from the international phase 3 AMPLTUDE clinical trial found that adding niraparib to abiraterone…
ASCO 2025: Addition of lurbinectedin to first-line maintenance treatment for small cell lung cancer prolongs survival, according to phase 3 trial
Small cell lung cancer (SCLC) accounts for approximately 15% of lung cancers, and most patients…
ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumour growth in glioblastoma. Tumours became…
ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer
The results of an international phase 3 clinical trial sponsored by the National Cancer Institute,…
ASCO 2025: Rusfertide shows promise for polycythemia vera treatment
Results from the Phase 3, randomised, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia…
ASCO 2025: Switch to camizestrant after liquid biopsy detection of breast cancer recurrence improves outcomes
A large prospective, randomised clinical trial in patients with advanced breast cancer has found that…